Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study.

Oncologist · 2025 · PMC12160817 · PMID 40504548

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

showed a trendP = .068so close (0.05 < p ≤ 0.1)

Specifically, the median OS was significantly longer in the PA-TACE plus LEN group (43.6 months vs 30.6 months, P = .037), while the median RFS showed a trend towards improvement (19.6 months vs 12.5 months, P = .068), as illustrated in Figure 2a and b .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.